SherrardD., BaylinkD., WergedalJ.. Bone disease in uremia. Trans ASAIO1972; 28: 412–5.
2.
LlachF., FelsenfeldA.J., ColemanM.D., KeveneyJ.J., PedersonJ.A., MedlockT.R.. The natural course of dialysis osteomalacia. Kidney Int1986; 29(suppl.): S74–9.
3.
SaluskyI.B., CoburnJ.W., BrillJ.Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int1988; 33: 975–82.
4.
SherrardD.I., HerczG., PeiY.The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int1993; 43: 436–42.
5.
TorresA., LorenzoV., HernandezD.Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better done response to PTH. Kidney Int1995; 47: 1434–42.
6.
CouttenyeM.M., D'HaeseP.C., DengI.T., Van HoofV.O., VerpootenG.A., De BroeM.E.. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant1997; 12: 2144–50.
7.
FournierA., SaidS., GhazaliA.Osteopathie adynamique de l'urémique: quelle signification clinique? In: Actualités Néphrologiques Jean Hamburger.Paris: Médicine-Sciences Flammarion, 1997: 95–128.
8.
MallucheH.H., Monier-FaugèreM-C. Risk of adynamic bone disease in dialyzed patients. Kidney Int1992; 42(suppl.): S62–7.
9.
KurzP., Monier-FaugèreM-C, BognarB.Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int1994; 46: 855–61.
10.
HutchisonAl, WhitehouseR.W., FreemontAl, AdamsJ.E., MawerB.B., GokalR.. Histological, radiological, and biochemical features of the adynamic bone lesion in continuous ambulatory peritoneal dialysis patients. Am J Nephrol1994; 14: 19–29.
11.
De VernejoulM.C., MarchaisS., LondonG., MorieuxC., BielakoffJ., MiravetL.. Increased bone aluminum deposition after subtotal parathyroidectomy in dialyzed patients. Kidney Int1985; 27: 785–91.
12.
FelsenfeldAl, MachadoL., RodriguezM.. The effect of high parathyroid hormone levels on the development of aluminum-induced osteomalacia in the rat. J Am Soc Nephrol1991; 1: 970–9.
13.
MallucheH.H., FaugèreM-C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int1990; 38: 193–211.
14.
Van HoofV.O., LepoutreL.G., HoylaertsM.F., ChevignèR., De BroeM.E.. Improved agarose electrophoretic method for separating alkaline phosphatase isoenzymes in serum. Clin Chem1988; 34: 1857–62.
15.
CouttenyeM.M., D'HaeseP.C., Van HoofV.O.Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant1996; 11: 1065–1072.
FournierA., MorinièreP., Cohen SolalM.E.Adynamic bone disease in uremia: may it be idiopathic? Is it an actual disease?Nephron1991; 58: 1–12.
18.
HernandezD., ConcepcionM.T., LorenzoV.Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant1994; 9: 517–23.
19.
MorinièreP., Cohen-SolalM., BelbrikS.Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron1989; 53: 93–101.
20.
PeiY., HerczG., GreenwoodC.Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res1995; 10: 149–56.
21.
FelsenfeldAl, RodriguezM., DunlayR., LlachF.. A comparison of parathyroid-gland function in haemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant1991; 6: 244–51.
CouttenyeM.M.. Adynamic bone disease in dialysis patients. Ph.D. thesis 1997: 123.
24.
MorriseyI., RothsteinM., MayorG.. Suppression of parthyroid hormone secretion by aluminium. Kidney Int1983; 23: 699–704.
25.
SmansK.A., D'HaeseP.C., Van LandeghemG.F.Transferrin-mediated uptake of aluminum by human parathyroid cells results in hypoparathyroidism. J Am Soc Nephrol (in press).
26.
Cohen-SolalM.E., SebertI.L., BoudailliezB.Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment?Bone1992; 13: 1–5.
27.
HernandezA., ConcepcionM.T., RodriguezM., SalidoE., TorresA.. High phosphorus diet increases preproPTHmRNA independent of calcium and calcitriol in normal rats. Kidney Int1996; 50: 1872–8.
28.
VincintiF., ArnaudS.B., ReckerR.Parathyroid and bone response of the diabetic patient to uremia. Kidney Int1984; 25: 677–82.
29.
CoburnW.. Mineral and renal bone disease: effects of CAPD versus hemodialysis. Kidney Int1993; 43(suppl.): S92–100.
30.
BurrittM.F., PieridisA.M., OffordK.P.. Comparative studies of total and ionized serum calcium values in normal subjects and patients with renal disorders. Mayo Clin Proc1980; 55: 606–13.
31.
HutchisonA.J., WhitehouseR.W., BoultonF.Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int1993; 44: 1071–7.
32.
MalbertiF., SurianM., MinettiL.. Dialysate calcium concentration decrease exacerbates secondary hyperparathyroidism in dialysis patients given calcium carbonate as a phosphate binder. J Nephrol1991; 2: 75–81.
33.
ArgilesA., KerrP.G., CanaudB., FlavierJ.L., MionC.. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int1993; 43: 630–40.
34.
Van der NiepenP., SennesaelJ., LouisO., VerbeelenD.. Effect of treatment with 1.25 and 1.75 mmol/L calcium dialysate on bone mineral density in haemodialysis patients. Nephrol Dial Transplant1995; 10: 2253–8.
35.
QuarlesL.D., LobaughB., MurphyG.. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab1992; 75: 145–50.
36.
UrenaP., KubruslyM., MannstadtM.The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int1994; 45: 605–11.
37.
UrenaP., MannstadtM., HrubyM.parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int1995; 47: 1797–805.
38.
UrenaP., FerreiraA., MorieuxC., DrüekeT., de VernejoulM.C.. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uremic rats. Nephrol Dial Transplant1996; 11: 2008–16.
39.
De VernejoulM.C., BelenguerR., HalkidouH., BuisineA., BielakoffJ., MiravetL.. Histomorphometric evidence of deleterious effect of aluminum on osteoblasts. Bone1985; 6: 15–20.
40.
ParisienM., CharhonS.A., ArlotM.Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease. J Bone Mineral Res1988; 3: 258–9.
41.
GoodmanW.G., RamirezI.A., BelinT.R.Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int1994; 46: 1160–6.
42.
InabaM., TeradaM., KoyamaH.Influence of high glucose on 1,25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res1995; 10: 1050–6.
43.
ArlotM., EdouardC., MeunierP.J., NeerR.M., ReeveJ.. Impaired osteoblast function in osteoporosis: comparison between calcium balance and dynamic histomorphometry. Br Med J1984; 289: 517–20.
44.
DelmasP.D.. Clinical use of biochemical markers of bone remodelling in osteoporosis. Bone1992; 13(suppl.): S17–21.
45.
AndressD.L., HowardG.A., BirnbaumR.S.. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int1991; 39: 942–5.
46.
FournierA., Hardy YverneauP., HuéP.Adynamic bone disease in patients with uremia. Curr Opin Nephrol and Hypert1994; 3: 396–410.
47.
DrüekeT.B.. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int1995; 48: 259–72.
